

Structure-Based Ligand Design

edited by Klaus Gubernator and Hans-Joachim Böhm

 **WILEY-VCH**

This Page Intentionally Left Blank

Structure-Based Ligand Design

edited by Klaus Gubernator and Hans-Joachim Böhm

 **WILEY-VCH**

Methods and Principles in Medicinal Chemistry

Edited by
R. Mannhold
H. Kubinyi
H. Timmerman

Editorial Board

F. Darvas, T. Fujita, C.R. Ganellin,
F. Gualtieri, U. Hacksell, H.-D. Höltje,
G. Leclerc, R. Rekker, J.-K. Seydel,
D. Triggle, H. van de Waterbeemd

Structure-Based Ligand Design

edited by
Klaus Gubernator
Hans-Joachim Böhm

 **WILEY-VCH**

Weinheim • New York • Chichester • Brisbane • Singapore • Toronto

Series Editors:

Prof. Dr. Raimund Mannhold
Biomedical Research Center
Molecular Drug Research Group
Heinrich-Heine-Universität
Universitätsstraße 1
D-40225 Düsseldorf
Germany

Prof. Dr. Hugo Kubinyi
ZHV/W, A 30
BASF AG
D-67056 Ludwigshafen
Germany

Prof. Dr. Hendrik Timmerman
Faculty of Chemistry
Dept. of Pharmacology
Free University of Amsterdam
De Boelelaan 1083
NL-1081 HV Amsterdam
The Netherlands

Volume Editors:

Dr. Klaus Gubernator
CombiChem Inc.
8050 Camino Santa Fe
San Diego, CA 92121
USA

Dr. Hans-Joachim Böhm
Hoffmann-La Roche AG
Pharma Research
4002 Basel
Switzerland

This book was carefully produced. Nevertheless, authors, editors and publisher do not warrant the information contained therein to be free of errors. Readers are advised to keep in mind that statements, data, illustrations, procedural details or other items may inadvertently be inaccurate.

Library of Congress Card No. applied for.

British Library Cataloguing-in-Publication Data: A catalogue record for this book is available from the British Library.

Deutsche Bibliothek Cataloguing-in-Publication Data:

Structure based ligand design / ed. by Klaus Gubernator ; Hans-Joachim Böhm. - Weinheim ; New York ; Chichester ; Brisbane ; Singapore ; Toronto : Wiley-VCH, 1998
(Methods and principles in medicinal chemistry ; Vol. 6)
ISBN 3-527-29343-4

© WILEY-VCH Verlag GmbH, D-69469 Weinheim (Federal Republic of Germany), 1998

Printed on acid-free and chlorine-free paper.

All rights reserved (including those of translation into other languages). No part of this book may be reproduced in any form – by photoprinting, microfilm, or any other means – nor transmitted or translated into a machine language without written permission from the publishers. Registered names, trademarks, etc. used in this book, even when not specifically marked as such, are not to be considered unprotected by law.

Composition: Datascan GmbH, D-67346 Speyer

Printing and Bookbinding: Franz Spiegel Buch GmbH, D-89026 Ulm

Printed in the Federal Republic of Germany.

Preface

Structure-based ligand design is defined as the search for molecules that fit into the binding pocket of a given target and that can form favorable interactions.

During the past few years, structure-based ligand design has gained an increasingly prominent position within medical chemistry. An impressive number of convincing examples have been published which prove the potential of this approach. Two factors underly the increasing importance and effort of structure-based ligand design: on the one hand, new computer programs for conformational analysis, ligand docking, structural alignment and *de novo* design have been developed; and on the other hand, scientific progress in the molecular biology providing the three-dimensional (3D) structure of therapeutically relevant biopolymers.

Despite such unquestionable progress, lead discovery by structure-based ligand design still faces several problems and limitations such as a lack of availability of 3D structures for the important group of membrane-bound receptors, or adequate computational approaches to reflect induced-fit in drug–receptor interactions.

With regard to the prime aim of our series, i.e. to provide practice-oriented information for medicinal chemists, Klaus Gubernator and Hans-Joachim Böhm have subdivided this volume into two parts. The first part comprises a concise introductory chapter, written by the editors, and covering all aspects of the methodological background in this research field. The second part comprises several chapters which summarize some success stories in the field of structure-based ligand design, such as the design of inhibitors of beta-lactamase (by Gubernator et al.), sialidase (by N. Taylor) or HIV-1 reverse transcriptase (by W. Schäfer). Progress in new computational approaches to predict protein–ligand interactions is described by H. J. Böhm.

The editors would like to thank the contributors to this volume for their cooperation. We are sure that scientists entering the field of structure-based ligand design will find in this volume the adequate support for the successful application of lead discovery techniques.

December 1997

Düsseldorf
Ludwigshafen
Amsterdam

Raimund Mannhold
Hugo Kubinyi
Henk Timmerman

Methods and Principles in Medicinal Chemistry

Edited by
R. Mannhold
H. Kubinyi
H. Timmerman

Volume 1

Hugo Kubinyi
QSAR: Hansch Analysis and Related Approaches

Volume 2

Han van de Waterbeemd (ed.)
Chemometric Methods in Molecular Design

Volume 3

Han van de Waterbeemd (ed.)
*Advanced Computer-Assisted Techniques in Drug
Discovery*

Volume 4

Vladimir Pliška, Bernard Testa, Han van de
Waterbeemd (eds.)
Lipophilicity in Drug Action and Toxicology

Volume 5

Hans-Dieter Höltje, Gerd Folkers
Molecular Modeling

Volume 6

Klaus Gubernator, Hans-Joachim Böhm
Structure-Based Ligand Design

A Personal Foreword

Writing or editing a book about a rapidly evolving area of science is a challenge. Doing this while being involved in real projects every day is even more of a challenge. And changing location and assignment during this exercise (which is true for both editors) adds further hurdles.

We are thus particularly glad to now present a series of real-life stories from practitioners in the field that have been selected to reflect the current status of structure-based design, its achievements and also its controversies. These are embedded in review-type methodological chapters and discussions about scope and future perspectives of these approaches.

Our personal summary from writing several chapters and editing others is that structure-based design actually works and its successes are now well documented. It cannot be applied to every project and the explosion of biostructural information has just started, dramatically broadening the scope of structure-based design in the future. The methodologies exploiting this information are still evolving and there is room for completely new approaches. This makes this field so interesting, in addition to the beauty of the 3D-structure, and makes writing an account or review so rewarding.

We would like to thank the contributors for the nice collaboration that we had. We also would like to acknowledge the continuous high interest of the series editors in this book project and their very valuable comments and suggestions on earlier versions of this work. We would also like to extend our thanks to our employers who fully support these additional activities, and to our families who have suffered from our mental absence for more than one weekend.

Summer 1997

San Diego

K. G.

Basel

H. J. B.

This Page Intentionally Left Blank

List of Contributors

Peter Angehrn
Hans-Joachim Böhm
Robert L. Charnas
Ingrid Heinze-Krauss
Christian Hubschwerlen
Christian Oefner
Malcolm P. G. Page
Fritz K. Winkler

Pharma Research
Hoffmann-La Roche AG
4070 Basel
Switzerland

Neera Borkakoti

Roche Products Limited
Broadwater Road
Welwyn Garden City
Herts AL7 3AY
UK

Klaus Gubernator

CombiChem, Inc.
9050 Camino Santa Fe
San Diego, CA 92121
USA

Christine Humblet
Elizabeth A. Lunney

Parke-Davis Pharmaceutical Research
Division of Warner-Lambert Company
2800 Plymouth Road
Ann Arbor
Michigan 48105-2430
USA

Wolfgang Schäfer

Chemical Research Department
Boehringer Mannheim GmbH
D-68298 Mannheim
Germany

Neil R. Taylor

Department of Biomolecular Structure
Glaxo Research and Development Ltd.
Medicines Research Centre
Gunnels Wood Road
Herts SG1 2NY
UK

This Page Intentionally Left Blank

Contents

Preface	V
List of Contributors	IX
1 Rational Design of Bioactive Molecules	
<i>K. Gubernator and H. J. Böhm</i>	1
1.1 Introduction	1
1.1.1 From Ligand Design to Drug Discovery	1
1.2 Source of Structural Information	2
1.3 Classes of Therapeutic Agents	3
1.4 Protein–Ligand Interaction	4
1.4.1 Covalent versus Noncovalent Inhibitors	4
1.4.2 Nonbonded Interactions in Protein–Ligand Complexes	4
1.4.3 Hydrogen Bonds	5
1.4.4 The Role of Solvent in Polar Protein–Ligand Interactions	5
1.4.5 Lipophilic Interactions	7
1.4.6 Criteria for Strong Protein–Ligand Interactions	7
1.5 Approaches to Structure-Based Ligand Design	8
1.5.1 Ligands Derived from Substrate or Natural Ligand	8
1.5.2 Structures Derived from 3D Database Searches	9
1.5.3 <i>De Novo</i> Design of Ligands	9
1.6 Methods and Tools used in Structure-Based Ligand Design	9
1.7 Outlook and Future Developments	10
References	11
2 Examples of Active Areas of Structure-Based Design	
<i>K. Gubernator and H. J. Böhm</i>	15
2.1 Thrombin Inhibitors	15
2.2 Design of Orally Active Inhibitors of Elastase	19
2.3 Dorzolamide: A Success Story of Structure-Based Drug Design	23
2.4 Inhibitors of Serine Esterases	26
2.4.1 Human Pancreatic Lipase (hPL)	26
2.4.2 Model of the Trilaurin Triglyceride Substrate Binding	27

2.4.3	Tetrahydrolipstatin (THL)	28
2.5	Acetylcholinesterase (AChE)	30
2.5.1	Model of the Acetylcholine Substrate Binding	31
2.5.2	Physostigmine	31
2.5.3	Eisai E2020	34
	References	35
3	From Renin to HIV-1 Protease	
	<i>E. A. Lunney and C. Humblet</i>	37
3.1	Introduction	37
3.2	Renin	38
3.2.1	Catalytic Site Binding	41
3.2.2	Backbone Variations	41
3.2.3	Subsite Interdependencies	44
3.2.4	Renin Crystal Structure	50
3.2.5	Summary – Renin Modeling	51
3.3	HIV-1 Protease	51
3.3.1	3D Structures of HIV-1 Protease	52
3.3.2	HIV-1 Protease Nonpeptide Inhibitors	55
3.3.3	Docking/Modeling HIV-1 Protease Nonpeptide Inhibitors	59
3.4	Summary: Comparison of HIV-1 Protease versus Renin Structure-Based Design	66
3.5	Current Limitations/Future Perspective	67
3.6	Conclusion	68
	References	69
4	Zinc Endoproteases: A Structural Superfamily	
	<i>N. Borkakoti</i>	73
4.1	Introduction	73
4.2	Structural Classification of Zinc Endopeptidase Families	74
4.2.1	Short Spacer or Metzincins Family	74
4.2.2	Long Spacer or Gluzincins Family	78
4.3	Overview of Inhibitor Design	80
4.4	Current Limitations	84
4.5	Future Prospects	85
	References	86
5	Structure-Based Design of Potent Beta-Lactamase Inhibitors	
	<i>K. Gubernator, I. Heinze-Krauss, P. Angehrn, R. L. Charnas, C. Hubschwerlen, C. Oefner, M. P. G. Page and F. K. Winkler</i>	89
5.1	Introduction	89
5.2	Structure of <i>Citrobacter freundii</i> Class C Beta-Lactamase	89
5.3	Model of the Mechanism of Action: Cleavage of Penicillin G	90

5.4	Structure of the Complex with Aztreonam	91
5.5	Design of Inhibitors	95
5.6	Kinetics of the Inhibition Reaction	96
5.7	Hydrolysis by Class A Beta-Lactamases	98
5.8	X-Ray Structure of the Complex with a Bridged Monobactam	99
5.9	Structure–Activity Relationship among Bridged Monobactams	100
5.10	Conclusion	102
	References	102
6	Inhibition of Sialidase	
	<i>N. R. Taylor</i>	105
6.1	Introduction	106
6.2	Influenza: Disease and Virus	107
6.3	Structure of Sialidase	108
6.4	Mechanism of Catalysis	109
6.5	Binding of Substrate and Transition State Mimics	110
6.6	Structure-Based Inhibitor Design	113
6.7	Enzyme–Inhibitor Interactions	114
6.8	Inhibitor Potency, Efficacy and Selectivity	116
6.9	Summary	117
	Acknowledgements	118
	References	118
7	Rational Design of Inhibitors of HIV-1 Reverse Transcriptase	
	<i>W. Schäfer</i>	119
7.1	Introduction	119
7.2	Building a Model	123
7.3	Test of the Model	124
7.4	Optimization of Compound 3	124
7.5	Design of a New Inhibitor	125
7.6	Guidelines and Conclusions	126
	References	127
8	New Computational Approaches to Predict Protein–Ligand Interactions	
	<i>H. J. Böhm</i>	129
8.1	Introduction	129
8.2	The Computer program LUDI	132
8.2.1	Basic Methodology	132
8.2.2	Applications of LUDI	136
8.3	Computational Methods to Predict Ligand Binding Affinities	137
8.3.1	A New Scoring Function for Protein–Ligand Complexes	138
8.4	Current Challenges in Computational <i>De Novo</i> Ligand Design	139

8.5	Summary	140
	References	140
9	The Future of Structure-Based Design: A Worthy Precept?	
	<i>H. J. Böhm and K. Gubernator</i>	143
9.1	Introduction	143
9.2	Developments in the Design Process	143
9.3	Screening Systems	145
9.4	Future Prospects	146
	Acknowledgement	147
	References	147
Index	149

1 Rational Design of Bioactive Molecules

K. Gubernator and H. J. Boehm

1.1 Introduction

During the past decade, medicinal chemistry has taken tremendous advantage of the fascinating scientific progress in the field of molecular biology. The three-dimensional (3D) structure determination of biopolymers is one such area which has developed extremely rapidly. As an ever-increasing number of 3D structures is now available, in medicinal chemistry the number of research projects in which the structure of the molecular target is known has rapidly increased. Therefore, there is strong interest both in industry and in academia to develop and apply new approaches that exploit such structural information in the drug discovery process. The purpose of the present volume is to summarize the current state of structure-based design and to present some interesting examples. This should convince the reader that structure-based ligand design has become a mature discipline of medicinal chemistry [1,2].

Structure-based ligand design is based on the observation that drugs bind to clearly defined molecular targets. A strong and selective binding can be obtained from a high structural and chemical complementarity between the macromolecular target and the ligand [3, 4]. Structure-based ligand design may therefore be described as the search for small molecules that fit into the binding site of the target and can form favorable interactions.

1.1.1 From Ligand Design to Drug Discovery

Structure-based design is now actively pursued by sizeable groups in both academic institutions as well as in the research departments of pharmaceutical companies. Very tight collaboration with both synthetic chemists as well as with experimental biologists performing the biological assay has turned out to be a critical success factor. This often results in the dissemination of structural information to all scientists involved in the project and, ideally, the persistent use of that information in the process of inventing new active principles.

Identifying a ligand to a given target is just the first step in the process of discovering a new drug that offers a therapeutic opportunity for the treatment of a disease. A number of further hurdles have to be taken by a compound until it also qualifies as a drug: It needs to be absorbed, transported, stable to metabolization, and distributed to the right compartment. It also has to be non-toxic, free of side effects, and chemically stable in a formulation. Most of these aspects are even more difficult to assess in a rational fashion. The ligand design part of the drug discovery process is therefore just the first step in a multidisciplinary effort that usually requires several rounds of refinement between the identification of an active principle and the selection of a viable drug candidate. Structure-based design can assist this continuous